Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > June 19, 2024
Daily News
June 19, 2024
- Concerns Grow over Supply of Cephem Antibiotics after Choseido Plant Halt
June 19, 2024
- Opposition Party Urges Health Minister to Scrap Off-Year Drug Price Revision
June 19, 2024
- MHLW to Bankroll Up to 50 Billion Yen Each to KM, Daiichi for Vaccine Trials
June 19, 2024
- J-TEC Files JACC for Label Expansion into Knee Osteoarthritis
June 19, 2024
- Otsuka, Ionis Extend HAE Licensing Pact into Asia
June 19, 2024
- Nitrosamine Risk Communication Guidance Issued, Effective Immediately
June 19, 2024
- Kidswell Bio, Chiome Hook Up on Biosimilar Development
June 19, 2024
- Mitsubishi Offloads Argatroban Business in Europe to Ethypharm
June 19, 2024
- Daiichi Sankyo President Reels in 200 Million Yen-Plus Pay in FY2023
June 19, 2024
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…